Dupixent Lawsuit Lawyer in Georgia | CTCL & T-Cell Lymphoma Claims

Last Updated: April 2026 | Written by Fob James IV, J.D., Mass Tort Attorney

Representing Georgia Patients Diagnosed With Lymphoma After Taking Dupixent (Dupilumab)

If you or a loved one in Georgia was prescribed Dupixent (dupilumab) and later developed cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, or Sézary syndrome, you may have grounds to file a Dupixent lawsuit against the drug’s manufacturers, Sanofi and Regeneron Pharmaceuticals.

At Fob James Law Firm, our mass tort attorneys represent Dupixent injury clients across Atlanta, Savannah, Augusta, Macon, Columbus, and throughout the state. We have recovered over $100 million for more than 1,000 clients in defective drug and product liability litigation nationwide. All Dupixent cases are handled on a contingency fee basis — you pay nothing unless we win.

Quick Answers: Dupixent Lawsuit Georgia

What Is Dupixent, and Why Are Georgia Patients Filing Lawsuits?

Dupixent (dupilumab) is an injectable biologic drug manufactured by Sanofi and Regeneron Pharmaceuticals. FDA-approved since 2017, Dupixent’s approved indications now include:

• Moderate-to-severe atopic dermatitis (eczema)
• Certain types of asthma
• Chronic rhinosinusitis with nasal polyps
• Eosinophilic esophagitis (EoE)
• Prurigo nodularis
• Chronic obstructive pulmonary disease (COPD)

In 2025, Dupixent generated $18.3 billion in global sales, making it one of the most commercially successful biologic drugs ever approved. Plaintiffs in Dupixent lawsuits allege that Sanofi and Regeneron prioritized those revenues over patient safety — specifically by failing to disclose a serious and documented risk of T-cell lymphoma.

The core allegation is straightforward: the manufacturers knew or should have known that Dupixent could cause, accelerate, or unmask cutaneous T-cell lymphoma in certain patients — and they never warned Georgia doctors or patients. As of April 2026, the word “lymphoma” does not appear anywhere in Dupixent’s FDA-approved prescribing label.

Why Georgia Is Ground Zero for Dupixent Litigation

Georgia occupies a uniquely important position in the Dupixent litigation landscape. In February 2026, Levin Papantonio attorneys Brandon L. Bogle and Madison Mougey filed a formal motion before the U.S. Judicial Panel on Multidistrict Litigation (JPML) to centralize all federal Dupixent CTCL lawsuits in a single MDL court. Their motion specifically proposed the Northern District of Georgia — Atlanta as the venue, citing the fact that more than 25% of all Dupixent federal cases filed to date are already pending there, more than any other district in the country.

For Georgia residents, this matters in two ways. First, it confirms that the harm associated with Dupixent is well-documented enough that national plaintiffs’ firms are actively litigating it — and that Georgia is their preferred battlefield. Second, it means Georgia Dupixent clients may benefit from coordinated federal discovery, shared expert witnesses, and efficient case management if the MDL is granted — all without giving up their individual claims or leaving the state for proceedings.

Cancers Linked to Dupixent: CTCL, PTCL, Mycosis Fungoides, and Sézary Syndrome

Two primary categories of T-cell malignancy have been associated with Dupixent use:

Cutaneous T-Cell Lymphoma (CTCL)

CTCL is a rare form of non-Hodgkin lymphoma in which malignant T-cells migrate to and proliferate in the skin. In its early stages, CTCL is nearly indistinguishable from atopic dermatitis — the same condition Dupixent is prescribed to treat. This is the central danger: by suppressing the visible inflammation that is a symptom of CTCL, Dupixent may mask the cancer’s presence while the disease continues to advance. When the true diagnosis is finally made — often after the disease has progressed to Stage III or IV — treatment options are more limited and outcomes are significantly worse.

The most common CTCL subtypes seen in Dupixent litigation include:

• Mycosis Fungoides — the most prevalent form, typically presenting as flat, scaly skin patches that partially respond to steroids, mimicking eczema
• Sézary Syndrome — an aggressive, systemic form affecting the blood and lymphatic system, causing widespread redness and severe immune dysfunction
• Primary cutaneous CD30+ T-cell lymphoproliferative disorders
• Extranodal NK/T-cell lymphoma

Peripheral T-Cell Lymphoma (PTCL)

Beyond CTCL, filed lawsuits and published case reports have also documented peripheral T-cell lymphoma (PTCL) following Dupixent use. In one 2026 Illinois lawsuit, a patient developed PTCL after receiving only five Dupixent injections, requiring chemotherapy and a stem cell transplant that led to additional complications including graft-versus-host disease. Our Georgia legal team evaluates both CTCL and PTCL claims.

Why CTCL Is So Often Misdiagnosed — and Why Dupixent Makes It Worse

The most dangerous aspect of the Dupixent-CTCL connection is that early-stage cutaneous T-cell lymphoma and atopic dermatitis can appear clinically identical — even to experienced dermatologists at Georgia’s leading medical centers. Both conditions present with:

• Red, inflamed, itchy skin patches
• Scaly or crusted plaques
• Lichenification — thickened, leathery skin texture
• Symptoms that flare and subside cyclically
• Partial response to topical corticosteroids

When a Georgia patient with undiagnosed CTCL is prescribed Dupixent, the drug suppresses the visible inflammation — creating the appearance that the eczema is improving. This apparent improvement reinforces the eczema diagnosis and removes the clinical urgency to investigate further. But beneath the surface, the malignancy continues progressing. By the time the true diagnosis is made, the window for early-stage treatment — which offers far better outcomes — has often closed.

Scientific Evidence Supporting Georgia Dupixent Lawsuits

Dupixent CTCL lawsuits are built on a substantial and growing body of peer-reviewed medical literature:

Large Database Studies

• JAMA Dermatology (April 2024): Study of 19,612 atopic dermatitis patients found Dupixent users were 4.1x more likely to develop CTCL (OR 4.1, 95% CI 2.1–8.2) vs. non-users. Most diagnoses occurred more than one year after starting Dupixent.
• Dermatologic Therapy (August 2024): TriNetX analysis of 1.18 million AD patients found 4.6x higher relative risk of CTCL (RR 4.6, 95% CI 2.5–8.6). Risk was highest in patients over 60 and within the first year of treatment.
• Journal of Allergy and Clinical Immunology (January 2025): FAERS and RNA-Seq analysis showing a 30x higher CTCL reporting rate for Dupixent vs. all other medications. Proposed mechanism: IL-13 pathway suppression accelerates malignant T-cell proliferation.
• European Respiratory Journal (June 2025): Population-based cohort of asthma patients — not eczema patients — found Dupixent users had 4.5x higher risk of CTCL compared to standard inhaler therapy patients. The risk signal extends beyond eczema.

FDA Adverse Event and Regulatory Actions

• March 2025: The FDA formally announced an investigation into the Dupixent-CTCL link and placed Dupixent on a watch list for medications with potentially serious risks. The agency is evaluating whether label updates are required.
• May 2025: FAERS analysis revealed 181,575 total Dupixent adverse event reports. The rate of CTCL-specific reports was approximately 30x higher than for all other drugs in the database.
• October 2025: FAERS contained nearly 300 lymphoma reports linked to Dupixent, including more than 138 CTCL cases.
• April 2026: Despite all of the above, the word ‘lymphoma’ still does not appear in Dupixent’s FDA-approved prescribing label — the failure-to-warn claim remains fully intact.

Case Series and Clinical Reports

• JAAD Case Reports (2022): Seven patients with severe atopic dermatitis developed or experienced worsening CTCL after starting Dupixent. Average time to CTCL diagnosis: 7.8 months.
• International Journal of Dermatology (2023): Systematic review of 18 cases. All patients had more than 50% body surface involvement before diagnosis; advanced stages (III/IV) were common.
• Blood Journal (November 2023): 25 patients at Memorial Sloan Kettering. Median time from Dupixent initiation to CTCL diagnosis: 10 months. Disease progression was often accelerated.

Warning Signs of Dupixent-Associated Lymphoma in Georgia Patients

If you are currently taking Dupixent and notice any of the following changes, contact your physician immediately. Do not stop your medication without medical guidance — but do specifically request evaluation for lymphoma:

• New or worsening skin patches, plaques, or nodules that are scaly, itchy, or burning
• Persistent red or purple skin lesions that do not respond to your eczema treatment as expected
• Thickened or tumorous skin areas, particularly on sun-protected parts of the body
• Swollen lymph nodes in the neck, armpits, or groin
• Unexplained weight loss, persistent night sweats, or recurring fevers — known as ‘B symptoms’
• Skin disease that initially improves on Dupixent, then worsens or behaves atypically
• Symptoms that a dermatologist describes as ‘resistant’ or ‘not typical’ eczema

Dupixent Lawsuit Status and Litigation Timeline — Updated April 2026

Legal Claims in a Georgia Dupixent Lawsuit

Georgia Dupixent lawsuits allege that Sanofi and Regeneron:

• Failed to warn Georgia patients and prescribers about the risk of CTCL and PTCL — the primary failure-to-warn theory under Georgia product liability law (O.C.G.A. § 51-1-11).
• Marketed Dupixent aggressively to capture $18+ billion in annual revenues while suppressing or ignoring emerging cancer signals from their own adverse event data.
• Failed to require prescreening protocols — such as T-cell clonality testing or skin biopsy — before prescribing Dupixent to adults with treatment-resistant or atypical dermatitis presentations.
• Failed to implement a ‘stop and investigate’ protocol requiring physicians to pause Dupixent when a patient’s symptoms deviate from typical eczema progression.
• Failed to update the Dupixent prescribing label despite receiving hundreds of CTCL adverse event reports submitted to the FDA.
• In wrongful death cases: caused or substantially contributed to the death of Georgia patients whose CTCL or PTCL diagnosis was delayed or accelerated by Dupixent use.

Georgia’s product liability statute, O.C.G.A. § 51-1-11, imposes strict liability on manufacturers of defective products that cause injury. In Dupixent cases, this means plaintiffs do not need to prove that Sanofi or Regeneron acted negligently — only that the product was defective (i.e., lacked adequate warnings) and that the defect caused the plaintiff’s harm.

Who Can File a Dupixent Lawsuit in Georgia?

You may be eligible to file a Georgia Dupixent lawsuit if:

• You were prescribed Dupixent for eczema, asthma, nasal polyps, EoE, COPD, or another approved indication.
• You were later diagnosed with cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, Sézary syndrome, or another T-cell or NK-cell malignancy.
• Your cancer diagnosis occurred during or after your Dupixent treatment, or your pre-existing but undiagnosed CTCL was allegedly accelerated or masked by Dupixent.
• You have medical records — including pathology reports and treatment records — documenting both your Dupixent use and your cancer diagnosis.
• Your claim can be filed within Georgia’s statute of limitations (see below).

Georgia family members of patients who died from T-cell lymphoma linked to Dupixent may also have standing to bring wrongful death claims under O.C.G.A. § 51-4-2. The first Dupixent wrongful death lawsuit was filed in October 2025. Contact our Georgia legal team immediately to evaluate your family’s options.

What Compensation Can Georgia Dupixent Victims Recover?

Under Georgia law, victims of Dupixent-related cancer injuries may be entitled to recover:

• Medical expenses — past treatment costs (chemotherapy, radiation, immunotherapy, stem cell transplants) and all future care costs
• Lost wages and loss of future earning capacity
• Pain and suffering
• Emotional distress and psychological harm
• Loss of enjoyment of life
• Wrongful death damages — including funeral and burial expenses, lost income, and loss of consortium for surviving family members

Georgia does not cap compensatory damages in product liability cases. Each case is evaluated based on the severity of injury, the extent of Dupixent use, the medical evidence connecting the drug to the diagnosis, and other case-specific factors. Our attorneys will provide a detailed damages analysis during your free case review.

Georgia Statute of Limitations for Dupixent Injury Claims

Under O.C.G.A. § 9-3-33, Georgia’s general statute of limitations for personal injury and product liability claims is two years from the date of injury or, under the discovery rule, two years from the date you discovered — or reasonably should have discovered — both the injury and its connection to Dupixent.

This discovery rule is especially significant in Dupixent cases. Many Georgia patients were diagnosed with CTCL months or years ago but had no reason to connect that diagnosis to Dupixent until the FDA announced its formal investigation in March 2025. For those patients, the two-year clock may have started running in 2025 — not on the date of their cancer diagnosis. However, this analysis is highly fact-specific.

Do not wait. Georgia courts apply statutes of limitations strictly. Missing the deadline — even by a single day — can permanently extinguish your right to compensation. Call our Atlanta-area legal team at 866-837-1010 for general background. Then contact us for a Georgia-specific evaluation.

Steps to Take If You Are a Georgia Dupixent Patient With a Cancer Diagnosis

1. Consult your physician before stopping Dupixent. Do not discontinue without medical supervision.
2. Request complete copies of your medical records, including dermatology notes, pathology and biopsy reports, and any oncology treatment records.
3. Document your Dupixent timeline: when you started, your dosage and frequency, when your symptoms changed, and the date of your cancer diagnosis.
4. Preserve all prescription records, pharmacy receipts, and insurance records related to Dupixent.
5. Contact Fob James Law Firm at 866-837-1010 for a free, confidential Georgia case evaluation.
6. Do not provide recorded statements to Sanofi, Regeneron, or their insurers or representatives without first speaking to a Dupixent attorney.

Why Choose Fob James Law Firm for Your Georgia Dupixent Lawsuit?

• Atlanta-area office at 1718 Peachtree St NW — local Georgia presence for face-to-face meetings and state court filings
• Licensed in Georgia, Alabama, and Tennessee — no need for local co-counsel in most Georgia matters
• Over $100 million recovered for 1,000+ clients in defective drug and injury claims across 48 states
• Access to board-certified dermatologists, oncologists, and immunologists for medical record review and expert analysis
• National mass tort resources — the infrastructure needed to take on Sanofi and Regeneron in federal court
• Contingency fee only — no upfront costs, no hourly fees, no out-of-pocket expenses unless we win
• Georgia cities served: Atlanta, Savannah, Augusta, Macon, Columbus, Athens, Albany, Gainesville, Warner Robins, and all surrounding communities

Frequently Asked Questions About Dupixent Lawsuits in Georgia

Is there a Dupixent recall in 2026?

No. As of April 2026, the FDA has not recalled Dupixent. The FDA formally announced an investigation into the drug’s link to CTCL in March 2025 and continues monitoring adverse event reports. Dupixent remains on the market with no cancer warning on its prescribing label.

What cancers are linked to Dupixent?

The primary cancers linked to Dupixent are cutaneous T-cell lymphoma (CTCL) — including mycosis fungoides and Sézary syndrome — and peripheral T-cell lymphoma (PTCL). Emerging research also suggests elevated risk of other T-cell and NK-cell malignancies.

Is there a Dupixent class action or MDL?

Dupixent cases are not class actions. In February 2026, plaintiffs’ attorneys filed a formal JPML motion to consolidate cases into a federal MDL, proposing the Northern District of Georgia — Atlanta — as the venue. As of late March 2026, approximately 18 federal cases were pending nationwide. A JPML ruling on MDL formation is expected mid-2026.

Why is Atlanta the proposed MDL venue?

Plaintiffs’ attorneys cited the Northern District of Georgia as the proposed MDL venue because more than 25% of all federal Dupixent cases — the highest concentration in any single district — are already filed there. It is also a centrally located, geographically convenient venue for parties and witnesses. This is a significant advantage for Georgia Dupixent clients.

What is the Georgia statute of limitations for a Dupixent lawsuit?

Under O.C.G.A. § 9-3-33, Georgia’s statute of limitations for personal injury claims is generally two years from the date of injury or discovery of the connection between Dupixent and your diagnosis. Because many Georgia patients only became aware of the FDA’s 2025 investigation recently, the clock may have started in 2025 for some. Contact our Georgia team immediately — this analysis is highly fact-specific and missing the deadline permanently bars your claim.

How much does it cost to hire a Georgia Dupixent lawyer?

Nothing upfront. Fob James Law Firm handle all Dupixent cases on a contingency fee basis. You owe nothing unless we win your case. There are no hourly fees, retainers, or out-of-pocket litigation costs.

Can my family file a wrongful death claim if a loved one died from Dupixent-linked lymphoma?

Yes. Under O.C.G.A. § 51-4-2, Georgia allows wrongful death claims when a manufacturer’s defective product causes death. The first Dupixent wrongful death lawsuit was filed nationally in October 2025. If a Georgia family member died from CTCL or PTCL linked to Dupixent, contact us for an immediate case evaluation.

I was prescribed Dupixent for asthma, not eczema. Can I still file a lawsuit in Georgia?

Potentially yes. A June 2025 study in the European Respiratory Journal found that asthma patients on Dupixent had a 4.5x higher risk of CTCL compared to patients on standard asthma medications. The cancer risk signal is not limited to eczema patients. Georgia asthma patients who developed CTCL or PTCL should contact us for a case review.

Is the Dupixent label defective under Georgia law?

Plaintiffs argue yes. Georgia’s product liability statute (O.C.G.A. § 51-1-11) imposes strict liability for defective products. A product that fails to warn of known or knowable risks is defective as a matter of law. As of April 2026, Dupixent’s label contains no warning about CTCL, PTCL, mycosis fungoides, or Sézary syndrome — despite hundreds of FDA adverse event reports and multiple peer-reviewed studies establishing a statistical association. Our Alabama Dupixent lawsuit page covers additional scientific background on the failure-to-warn theory.

How do I start a Dupixent claim in Georgia?

Call Fob James Law Firm at 866-837-1010, or complete our online case evaluation form. Our Georgia legal team will review your medical history, explain your rights under Georgia law, and guide you through every step of the process — at no charge until we win.

Contact a Georgia Dupixent Lawsuit Lawyer Today — Free Consultation

If you or a family member in Georgia developed T-cell lymphoma, CTCL, PTCL, mycosis fungoides, or Sézary syndrome after taking Dupixent, do not wait. Georgia’s statute of limitations runs strictly, and early action improves your case positioning — especially as MDL formation approaches.

Call Fob James Law Firm at 866-837-1010 or complete our online form for a free, confidential Georgia case evaluation. Our Atlanta-area team serves clients throughout Georgia, including Atlanta, Savannah, Augusta, Macon, Columbus, Athens, Albany, and every surrounding community.

Our Dupixent lawsuit lawyers are ready to fight for your rights and hold Sanofi and Regeneron accountable.